BPG is committed to discovery and dissemination of knowledge
Featured Articles
8/21/2025 9:05:20 AM | Browse: 3 | Download: 5
 |
Received |
|
2025-04-02 08:20 |
|
Peer-Review Started |
|
2025-04-02 08:20 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2025-05-15 00:38 |
|
Revised |
|
2025-05-28 07:01 |
|
Second Decision |
|
2025-07-14 02:42 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2025-07-14 09:52 |
|
Articles in Press |
|
2025-07-14 09:52 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-08-07 01:51 |
|
Publish the Manuscript Online |
|
2025-08-21 08:16 |
| ISSN |
1949-8462 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Endocrinology & Metabolism |
| Manuscript Type |
Evidence Review |
| Article Title |
Efficacy and safety of incretin co-agonists: Transformative advances in cardiometabolic healthcare
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Sowrabha Bhat, Cornelius J Fernandez, Vijaya Lakshmi and Joseph M Pappachan |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Joseph M Pappachan, Academic Editor, FRCP, MD, MRCP, Professor, Senior Researcher, Faculty of Science, Manchester Metropolitan University, Oxford Road, Manchester M15 6BH, United Kingdom. drpappachan@yahoo.co.in |
| Key Words |
Incretin co-agonists; Incretin poly-agonists; Metabolic health; Type 2 diabetes mellitus; Obesity; Cardiovascular safety |
| Core Tip |
Several incretin co-agonists have been developed in the recent years with outstanding metabolic and weight loss benefits revolutionising management of obesity and type 2 diabetes mellitus (T2DM). Management of obesity and T2DM with these glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide/glucagon co-agonists/poly-agonists are associated with remarkable weight loss, improvement of glycated hemoglobin, albuminuria, lipid profile, liver fat and sleep apnea among patients. All these benefits are also associated with marked improvement in cardiovascular outcomes in patients treated with these medications. This clinical update review explores current evidence and emerging research questions regarding the cardiometabolic benefits associated with rational use of incretin co-agonists. |
| Publish Date |
2025-08-21 08:16 |
| Citation |
<p>Bhat S, Fernandez CJ, Lakshmi V, Pappachan JM. Efficacy and safety of incretin co-agonists: Transformative advances in cardiometabolic healthcare. <i>World J Cardiol</i> 2025; 17(8): 107991</p> |
| URL |
https://www.wjgnet.com/1949-8462/full/v17/i8/107991.htm |
| DOI |
https://dx.doi.org/10.4330/wjc.v17.i8.107991 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
